trial · primary record
Cadonilimab
Endometrial Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 10 |
| Primary completion | 2033-04-01 |
| Primary endpoint | Complete Response Rate (CRR) |
| Registry ID | NCT07900256 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:46.955Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07900256
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.